• Home
  1. Home
  2. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
Scientific article
OA Policy
English

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis

ContributorsGabay, Cem; McInnes, Iain B; Kavanaugh, Arthur; Tuckwell, Katie; Klearman, Micki; Pulley, Jennifer; Sattar, Naveed
Published inAnnals of the rheumatic diseases, vol. 75, no. 10, p. 1806-1812
Publication date2016
Abstract

Compare changes in lipids and lipid-associated cardiovascular (CV) risk markers in patients with rheumatoid arthritis (RA) treated with tocilizumab or adalimumab.

Affiliation entities
Research groups
Citation (ISO format)
GABAY, Cem et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. In: Annals of the rheumatic diseases, 2016, vol. 75, n° 10, p. 1806–1812. doi: 10.1136/annrheumdis-2015-207872
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN0003-4967
565views
262downloads

Technical informations

Creation31/08/2016 16:48:00
First validation31/08/2016 16:48:00
Update24/01/2025 14:31:57
Status update24/01/2025 14:31:57
Last indexation24/01/2025 14:40:06
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack